clindamycin navamedic 600 mg infuusioneste, liuos
navamedic asa - clindamycin phosphate - infuusioneste, liuos - 600 mg - klindamysiini
rivaroxaban avansor 20 mg tabletti, kalvopäällysteinen
avansor pharma oy - rivaroxaban - tabletti, kalvopäällysteinen - 20 mg - rivaroksabaani
rivaroxaban avansor 15 mg tabletti, kalvopäällysteinen
avansor pharma oy - rivaroxaban - tabletti, kalvopäällysteinen - 15 mg - rivaroksabaani
rivaroxaban avansor 10 mg tabletti, kalvopäällysteinen
avansor pharma oy - rivaroxaban - tabletti, kalvopäällysteinen - 10 mg - rivaroksabaani
metformin zentiva 1000 mg tabletti, kalvopäällysteinen
zentiva, k.s. - metformin hydrochloride - tabletti, kalvopäällysteinen - 1000 mg - metformiini
metformin zentiva 850 mg tabletti, kalvopäällysteinen
zentiva, k.s. - metformin hydrochloride - tabletti, kalvopäällysteinen - 850 mg - metformiini
metformin zentiva 500 mg tabletti, kalvopäällysteinen
zentiva, k.s. - metformin hydrochloride - tabletti, kalvopäällysteinen - 500 mg - metformiini
ticagrelor avansor 90 mg tabletti, kalvopäällysteinen
avansor pharma oy - ticagrelorum - tabletti, kalvopäällysteinen - 90 mg - tikagrelori
ticagrelor avansor 60 mg tabletti, kalvopäällysteinen
avansor pharma oy - ticagrelorum - tabletti, kalvopäällysteinen - 60 mg - tikagrelori
ranivisio
midas pharma gmbh - ranibitsumabi - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - silmätautien - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).